Pharmacia valdecoxib
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NDA for the second-generation COX-2 inhibitor submitted in January for the treatment of acute pain, dysmenorrhea, osteoarthritis and rheumatoid arthritis. The drug, which is expected to receive a 12-month review, will be co-promoted with Pfize